Clinical trial with ATAC candidate HDP-101 in multiple myeloma shows promising data Cohort 7 of the Phase I dose escalation study with HDP-101 safe and well tolerated; Cohort 8 started First patient in clinical study dosed with the second ATAC candidate HDP-102 in the non-Hodgkin lymphoma (NHL) indication Amendment of contract with HealthCare Royalty; payment of […]
Licensing agreement gives Elevation Oncology access to Synaffix’s ADC technology for one program in combination with SYNstatin E™ Elevation Oncology nominates a novel HER3 ADC candidate EO-1022 leveraging its antibody as well as Synaffix’s proprietary ADC development technologies AMSTERDAM, THE NETHERLANDS, 12 December 2024 — Synaffix B.V., a Lonza company (SIX:LONN) focused on commercializing its […]
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies Collaboration underscores Lonza’s commitment to helping customers deliver innovative new therapies to patients by offering a comprehensive service offering for differentiated ADCs BigHat’s artificial intelligence (AI)/machine learning (ML)-powered antibody design platform, Milliner™ was used to design a highly differentiated […]
Ladenburg, Germany, 19 March 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced the formal closing of the royalty purchase agreement with HealthCare Royalty (HCRx) for Zircaix®, signed earlier this month. Under the terms of the agreement, Heidelberg Pharma has received an upfront, non-refundable cash payment of […]
Data from HDP-101 dose escalation shows first objective responses and partial remissions in Cohort 5 Amended protocol includes expanded Cohort 6 with dose optimization, including three parallel arms at different dosing regimens Revolutionizing treatment options for multiple myeloma patients with its proprietary novel payload with a unique mode of action Ladenburg, Germany, 18 March 2024 […]
